Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03642691
- Locations
- 🇺🇸
Tower Hematology and Oncology, Beverly Hills, California, United States
🇺🇸Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03265171
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
- Conditions
- HypoplasminogenemiaCongenital Plasminogen Deficiency
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02690714
- Locations
- 🇺🇸
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
🇳🇴Oslo University Hospital HF, Oslo, Sognsvannvejen 20, Norway
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
- Conditions
- Type I Plasminogen DeficiencyHypoplasminogenemia
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02312180
- Locations
- 🇺🇸
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
- Conditions
- Primary Immunodeficiency
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02269163
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Immunoe International Research, Centennial, Colorado, United States